These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25868469)

  • 21. Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.
    Aronsson M; Svennberg E; Rosenqvist M; Engdahl J; Al-Khalili F; Friberg L; Frykman V; Levin LÅ
    Europace; 2017 Oct; 19(10):1650-1656. PubMed ID: 28340009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals.
    van Kempen BJ; Spronk S; Koller MT; Elias-Smale SE; Fleischmann KE; Ikram MA; Krestin GP; Hofman A; Witteman JC; Hunink MG
    J Am Coll Cardiol; 2011 Oct; 58(16):1690-701. PubMed ID: 21982314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening.
    Orchard J; Li J; Freedman B; Webster R; Salkeld G; Hespe C; Gallagher R; Patel A; Kamel B; Neubeck L; Lowres N
    J Am Heart Assoc; 2020 Sep; 9(18):e017080. PubMed ID: 32865129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
    Åkerborg Ö; Nilsson J; Bascle S; Lindgren P; Reynolds M
    Clin Ther; 2012 Aug; 34(8):1788-802. PubMed ID: 22770643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland.
    Moran PS; Teljeur C; Harrington P; Smith SM; Smyth B; Harbison J; Normand C; Ryan M
    Value Health; 2016 Dec; 19(8):985-995. PubMed ID: 27987649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of one-time opportunistic screening for atrial fibrillation in different age cohorts of inhabitants in Denmark aged 65 years and above: a Markov modelled analysis.
    Sciera LK; Frost L; Dybro L; Poulsen PB
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):177-186. PubMed ID: 33337469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting.
    Desteghe L; Raymaekers Z; Lutin M; Vijgen J; Dilling-Boer D; Koopman P; Schurmans J; Vanduynhoven P; Dendale P; Heidbuchel H
    Europace; 2017 Jan; 19(1):29-39. PubMed ID: 26893496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of screening for atrial fibrillation in a single primary care center at a 3-year follow-up.
    Ghazal F; Aronsson M; Al-Khalili F; Rosenqvist M; Levin LÅ
    Scand Cardiovasc J; 2022 Dec; 56(1):35-41. PubMed ID: 35389311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Effect and Cost-Effectiveness of Screening for Asymptomatic Carotid Stenosis: A Markov Model.
    Högberg D; Mani K; Wanhainen A; Svensjö S
    Eur J Vasc Endovasc Surg; 2018 Jun; 55(6):819-827. PubMed ID: 29636252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of screening for paroxysmal atrial fibrillation in patients undergoing echocardiography.
    Ramkumar S; Kawakami H; Wong E; Nolan M; Marwick TH
    Intern Med J; 2023 May; 53(5):760-772. PubMed ID: 35377542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of Using Mobile ECG Recording Technology to Detect Atrial Fibrillation in Low-Resource Settings.
    Evans GF; Shirk A; Muturi P; Soliman EZ
    Glob Heart; 2017 Dec; 12(4):285-289. PubMed ID: 28302547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England.
    Hill NR; Groves L; Dickerson C; Boyce R; Lawton S; Hurst M; Pollock KG; Sugrue DM; Lister S; Arden C; Davies DW; Martin AC; Sandler B; Gordon J; Farooqui U; Clifton D; Mallen C; Rogers J; Camm AJ; Cohen AT
    J Med Econ; 2022; 25(1):974-983. PubMed ID: 35834373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.